

Smilow Auditorium • 55 Park Street • 12:00 Noon

April 10, 2018 Yale SPORE in Skin Cancer

Yvonne Saenger, MD

Director, Melanoma Immunotherapy, Herbert Irving
Comprehensive Cancer Center

Quantitative Immune Biomarkers in Early Stage Melanoma

Needs: There are newer pathology methods that need to be understood in the assessment of the tumor micro-environment and also risk assessments in early stage melanoma.

Objectives: To assess the risk of recurrence in early stage melanoma and to learn basic concepts of immune surveillance in cancer.

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. **Target Audience:** YCC members, Smilow faculty, YSM, Nursing, Public Health Students **Faculty Disclosures:** Dr. Fuchs, none. Saenger, Amger. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**